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Identity 
Other names: NMT 




The gene located on the forward strand and spans a size 
of 47705 bases. It starts at 43138680 and ends at 





No known pseudogenes. 
Protein 
Description 
N-myristoyltransferase 1 (NMT 1: EC 2.3.1.97) is a 
key cellular enzyme which carries out lipid 
modification by facilitating the attachment of myristate 
to the N-terminal glycine of several protein molecul s. 
The enzyme's function is indispensible for the growth 
and development of many eukaryotic organisms and 
several rotaviruses (Duronio et al., 1989; Duronio et al., 
1991; Maurer-Stroh and Eisenhower, 2004; Yang et al., 
2005; Wright et al., 2009). The best studied homologue 
of NMT1 is from the S. cerevisiae (Farazi et al., 2001).  
It is a monomer and does not require any cofactor or 
post-translational modifications. The enzyme follows 
an ordered Bi Bi reaction mechanism in which the apo-
enzyme binds myristoyl-CoA to form a NMT1-
myristoyl-CoA binary complex which subsequently 
binds to protein/peptide substrates. The catalytic 
conversion (N-myristoylation) is via a direct 
nucleophilic addition-elimination reaction. The 
sequential release of CoA and myristoyl-peptide 
follows the formation of an enzyme-product complex 
from the enzyme-substrate complex (Farazi et al., 
2001; Wright et al., 2009). N-myristoyltransferases 1 
have a common preference for myristoyl-CoA but have 
divergent peptide substrate specificities and the enzyme 
is highly selective for myristoyl-CoA in vitro and in 
vivo (Farazi et al., 2001). The protein belongs to 
GNAT superfamily of enzymes and consists of a 
saddle-shaped beta-sheet flanked by a helices. There is 
a pseudo two fold symmetry with regions 
corresponding to N- and C-terminal portions of the 
enzyme. The N-terminal half forms the myristoyl-CoA 
binding site whereas the C-terminal half forms the 
major portion of the peptide binding site (Farazi et al., 
2001; Wright et al., 2009). A large number of crystal 
structures of NMT1 from yeast and human isoforms are 
available in apo and complex form. Comparative 
analysis of the various NMTs has shown that the 
peptide binding pocket is more divergent than the 
myristoyl-CoA-binding site (Farazi et al., 2001; Wright 
et al., 2009). Further, the phospho-proteome analysis 
studies have shown that the human isoform is 
phosphorylated in vivo at position 47 (Beausoleil et al., 
2004; Beausoleil et al., 2006; Olsen et al., 2006;  
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Dephoure et al., 2008; Mayya et al., 2009). However 
the biological significance of this observation is not yet 
established. 
Expression 
The enzyme is ubiquitous in expression and often exists 
as isozymes in vivo, varying in either apparent 
molecular weight and/or subcellular distribution 
(Selvakumar et al., 2007; Wright et al., 2009). In 
humans NMT1 is processed to exist as four distinct 
isoforms ranging from 49 to 68 kDa in size (Giang ad 
Cravatt, 1998). The longer isoform of 496 amino acids 
represents the full-length protein whereas the shorter 
isoform represents a translation product of 416 amino 
acids that initiates with a methionine at amino acid 
position 81 in the full-length cDNA (Giang and 
Cravatt, 1998; Farazi et al., 2001). The shorter isoform 
of NMT1 may arise from an alternative splice variant 
or through initiation of translation at an internal 
methionine. 
Localisation 
NMT1 is a cytoplasmic enzyme because of N-
myristoylation being a co-translational protein 
modification. Recently, it has been reported that the
extended N-terminal domain of the longer isoform of 
NMT1 is involved in targeting the enzyme to the 
ribosome but it is not required for activity in vitro 
(Glover et al., 1997). Targeting to the ribosome appears 
to be consistent with its role as a co-translational 
protein modifier. In previous studies it has been 
observed that NMT1 activity from various cell lines 
and tissues is associated with membranous and 
particulate fraction (Magnuson et al., 1995; Boutin, 
1997). However, the enzyme activity in particulate 
fractions in earlier studies could represent an 
association with ribosomes, rather than an authentic 
membrane association. 
Function 
N-myristoyltransferase1 catalyses the covalent 
attachment of myristate, a 14 carbon saturated fatty 
acid, via amide bond to the N-terminal glycine residue 
of several proteins (Wright et al., 2009; Hannoush and
Sun, 2010). This lipidic modification is an irreversible 
process, however not without exceptions (Hannoush 
and Sun, 2010). Intially this process was thought to be 
co-translational in which the addition of myristate on 
the N-terminal glycine takes place after initial amino 
acid residues (within 100) have been synthesized by the 
ribosome (Wilcox et al., 1987). The process follows 
after the removal of the initiator methionine by a 
methionine aminopeptidase to expose an available N-
terminal glycine. However, now it has been shown to 
occur post-translationally as well when an internal 
glycine within a polypeptide chain is exposed 
following a proteolytic cleavage (Zha et al., 2000; 
Utsumi et al., 2003; Martin et al., 2008). The 
Availability of exposed N-terminal glycine is an 
absolute requirement and the modification occurs on a 
general consesus motif of GXXXS/T (where X is any 
amino acid) (Boutin, 1997; Resh, 1999; Farazi et al., 
2001; Wright et al., 2009; Hannoush and Sun, 2010).  
Various regular endogenous, physiological enzymes 
and proteins such as protein kinase A, protein kinase G, 
NADH-cytochrome b5 reductase, nitric oxide synthase, 
recoverin, most of the G protein a subunit are the 
substrates of myristoylation among higher eukaryotes. 
A detailed list of the substrate proteins is available in a 
number of reviews elsewhere (Boutin, 1997; Resh, 
1999; Maurer-Stroh et al., 2004; Selvakumar et al., 
2007). Myristoylation increases protein lipophilicity 
and is important for the full expression of biological 
functions of proteins. It controls the functioning of
proteins by targeting them to specific localization, 
promoting specific protein-protein and protein-lipid 
interactions and ligand-induced conformational 





Altered NMT expression is observed in many types of 
cancer tissues including those of colon, breast, 
gallbladder and brain (Selvakumar et al., 2007; Wright 
et al., 2009). A quantitative RT-PCR investigation f 
hNMT-1 expression during the progression of different 
human cancers shows that hNMT-1 is upregulated in 
breast, colon, lung and on average by 3.7 (p=0.032), 
3.1 (p=0.001), 2.3 (p=0.003) and 1.8 (p=0.012) fold, 
respectively (Chen et al., 2009). These findings are
explained by the hypothesis that many of the various 
proteins/oncoproteins (src, ras etc.) which are 
overexpressed and activated, during tumorigenesis 
require myristoylation for their proper function 
(Boutin, 1997; Resh, 1999; Wright et al., 2009). The 
elevated NMT activity accounts for the functioning of 
overexpressed oncoproteins and NMT thus plays a role 
in cancer progression. The NMT substrate src has 
elevated activity in human cancers and this contributes 
to its pathogenicity (Frame, 2002). Inhibiting NMT1 
functions has also been shown to reduce proliferation 
and induce apoptosis in human and murine melanoma 
cell lines and also to block tumor growth in vivo 
(Bhandarkar et al., 2008). The siRNA mediated NMT1 
knockdown shows that silencing NMT1 inhibits cell 
replication associated with loss of c-Src activation and 
its target FAK as well as reduction of various protein 
kinase regulated pathways (Ducker et al., 2005). The
knockdown of either of the isozymes, NMT1 or NMT2 
results in apoptosis with NMT2 having a more 
pronounced effect than NMT1. However, in a mouse 
model the intratumoral injection mainly of NMT1 
siRNA has been shown to be responsible for inhibition 
of tumor growth (Ducker et al., 2005). It has been 
concluded that among the two isoforms of NMT 
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(NMT1 and NMT2), both have only partially 
overlapping functions and that NMT1 is critical for 
tumor cell proliferation further suggesting that isoform-
specific inhibitors might be developed as potential anti-
cancer agents (Ducker et al., 2005). It is now apparent 
that NMT represents both a valuable clinical marker 
and therapeutic target for cancer (Boutin, 1997; Ducker 
et al., 2005; Selvakumar et al., 2007; Wright et al.,
2009). A several fold increase in NMT activity in 
polyps and stage B1 tumors compared to normal 
colonic mucosa have been proposed to be used as a 
diagnostic/prognostic tool for early detection of 
colorectal cancer (Raju et al., 1997; Shrivastav et al., 
2007; Kumar et al., 2011). 
Colorectal cancer 
Disease 
Colorectal cancer is associated with significantly high 
mortality and is one of the most common forms of 
malignancy world wide (Segal and Saltz, 2009). In the 
western world, it accounts for the second most commn 
cause of cancer associated deaths (Midgley and Kerr, 
2001; Tol and Punt, 2010) and is the fourth most 
common cause of malignancy in the United States 
(Wolpin et al., 2007; Wolpin and Mayer, 2008). A 
majority of colon cancer develop from the pre-
cancerous polyps on the lining of the colon which grow 
over the years to becomes cancerous in nature (Midgley 
and Kerr, 1999). With the increasing armentarium 
towards colon cancer (Midgley and Kerr, 1999; 
Midgley and Kerr, 2001; Wolpin et al., 2007; Wolpin 
and Mayer, 2008; Segal and Saltz, 2009; Tol and Punt, 
2010), it is one of the most curable forms of cancer if 
detected early. However, due to the lack of early 
symptoms, the majority of the patients have an 
advanced disease at presentation (Midgley et al., 2001; 
Segal and Saltz, 2009). Studies have shown that NMT 
represents both a valuable marker for clinical diagnosis 
and as a therapeutic target for colon cancer (Magnuso  
et al., 1995; Raju et al., 1997; Shrivastav et al., 2007; 
Kumar et al., 2011). 
Prognosis 
A direct relationship has been reported for NMT 
expression and activity and colon cancer progression 
(Magnuson et al., 1995; Raju et al., 1997). NMT 
activity and expression has been shown to be 
upregulated during the progression of colorectal cancer 
(Magnuson et al., 1995; Raju et al., 1997) and NMT 
thus has been proposed as a potential chemotherapeutic 
target (Felsted et al., 1995). A significantly higher 
NMT activity in rat colonic tumors and a several fold 
increase in NMT activity in polyps and stage B1 
tumors compared to normal colonic mucosa have 
indicated that NMT could be used as a 
diagnostic/prognostic tool for colorectal cancer 
(Magnuson et al., 1995; Raju et al., 1997; Shrivastav et 
al., 2007). Altered expression and localization of NMT 
in the peripheral blood and bone marrow of colon  
cancer patients have offered an advantage for early 
detection of colorectal cancer using NMT as a blood 
based marker (Shrivastav et al., 2007; Kumar et al., 
2011). The immunohistochemical analysis shows weak 
to negative staining for NMT in peripheral blood 
mononuclear cells (PBMC) of controls, whereas strong 
positivity is observed in the PBMC of colon cancer 
patients (Shrivastav et al., 2007; Kumar et al., 2011). In 
addition, NMT is confined mostly in the nuclei of the 
bone marrow (BM) mononuclear cells of the colon 
cancer patients, whereas in the control bone marrow 
specimens it remained cytoplasmic. The strikingly 
different NMT expression and its altered localization 
offers the basis of a potential adjunct investigative ool 
for screening or diagnosis of patients at risk for, r 
suspected of having, colon cancer (Shrivastav et al., 
2007; Kumar et al., 2011). It has been observed that in 
colon cancer cell lines, an elevated expression of NMT 
correlates with high levels of c-Src levels (Rajala et al., 
2000a). Further it has been observed that the levels of 
the myristoylated tyrosine kinases, pp60c-src and pp60c-
yes are several fold higher in colonic preneoplastic 
lesions and neoplasms compared with normal colon 
cells (Bolen et al., 1987; Weber et al., 1992; Termuhlen 
et al., 1993). Differential expression of pp60c-src has 
been observed in colonic tumor-derived cell lines 
(Bolen et al., 1987; Weber et al., 1992) and colonic 
polyps prone to developing cancer (Cartwright et al., 
1990). In the intestinal crypt cells, higher levels of 
cytoskeletal-associated pp60c-src protein tyrosine kinase 
activity have been observed along with higher 
expression of pp60c-yes in the normal intestinal 
epithelium (Zhao et al., 1990; Cartwright et al., 1993). 
Studies have revealed that pp60c-src is overexpressed in 
human colon carcinoma and it has enhanced kinase 
activity in progressive stages and metastases of human 
colorectal cancer (Bolen et al., 1987; Termuhlen et al., 
1993). Furthermore, it has been shown that src kinase 
activity is positively regulated by myristoylation and 
the non-myristoylated c-Src exhibited has reduced 
kinase activity (Patwardhan and Resh, 2010). The 
blockages of pp60c-src N-myristoylation in colonic cell 
lines have been reported to result in depressed colony 
formation and reduced proliferation (Shoji et al., 1990). 
Gallbladder cancer 
Disease 
Gallbladder cancer, also known as carcinoma of the 
gallbladder, is extremely rare affecting the gall bladder 
(the organ behind the liver which stores bile  
produced by the liver). Gallbladder is a non-essential 
organ and can be removed without significant 
consequences. However, since gallbladder cancer is 
very uncommon and many of its symptoms are similar 
to those of more common ailments (jaundice, pain, and 
fever), cancer of the gallbladder is usually not found 
until it is at an advanced stage and cannot be surgically 
removed. 
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Prognosis 
Gallbladder cancer tends to spread to the liver or small 
intestine and also spreads to lymph nodes through the 
lymphatic system in the region of the liver resulting in 
involvement of other lymph nodes and organs. The 
treatments available are not particularly effective, 
unless the tumor is very small and found in which case 
the gallbladder is removed for other reasons. A study of 
documented gallbladder carcinoma cases has been 
evaluated for NMT and p53 expression by 
immunohistochemistry in both in situ and in invasive 
tumor components (Rajala et al., 2000b). Moderate to 
strong cytoplasmic positivity for NMT with increased 
intensity in the invasive component was observed in 
60% of the cases. A mild to moderate cytoplasmic 
staining was revealed in the in situ component in 67% 
of the cases studied. It has been concluded that 
increased NMT expression in gall bladder tumors is 
associated with poor clinical outcomes as evidenced by 
their mean survival times (Rajala et al., 2000b). 
Breast cancer 
Disease 
Breast cancer originates from the breast tissue, most 
commonly from the inner lining of milk ducts (ductal 
carcinoma) or the lobules (lobular carcinoma) that 
supply the ducts with milk. It is the fifth most common 
cause of cancer death and comprises 10.4% of all 
cancer incidences among women worldwide, and is the 
most common type of non-skin cancer in women. 
Prognosis 
It has been observed that in the mammary epithelial 
cells, the proliferative capacity correlates with NMT 
activity (Clegg et al., 1999). A study of the NMT 
profiles in tumourigenic or metastatic breast cancer cell 
lines have displayed reduced NMT activity and western 
blot analysis shows that NMT1 is phosphorylated in 
these breast cancer cells (Shrivastav et al., 2009). 
Furthermore, patients' breast cancer tissue array 
revealed strong positivity and high intensity for NMT 
in malignant breast tissues compared with normal 
breast cells. In the grade I, II, and III infiltrating ductal 
carcinoma breast tissues, a gradation in the NMT 
staining was observed (Shrivastav et al., 2009). It has 
been concluded that NMT may prove to be an 
additional diagnostic biomarker for breast cancer. 
HIV infection 
Disease 
The human immunodeficiency virus (HIV) is a member 
of the retrovirus family (lentivirus) that causes acquired 
immune deficiency syndrome (AIDS). In this syndrome 
the immune system begins to fail leading to life-
threatening opportunistic infections. The major routes 
of infections are via the transfer of blood, breast milk, 
semen, vaginal fluid and the pre-ejaculate. If left 
untreated, the progressive failure of the immune system  
 
results in opportunistic infections or malignancies 
leading to the death of individuals in most of the cases. 
Prognosis 
The pathogenic states linked to undesired 
myristoylation activity includes the myristoylation of 
viral proteins for their proper maturation and infectivity 
(Boutin, 1997; Maurer-Stroh and Eisenhower, 2004; 
Wright et al., 2009). Many of the viral genes are 
homologues of the tyrosine kinases and require N-
myristoylation for the infectivity of viral particles. In 
the case of HIV infections, viral proteins Gag and Nef 
require myristoylation by the host cell NMT to carry 
out their function properly. Gag is the precursor 
polyprotein for structural components of the viral 
capsid and requires myristoylation for intracellular 
localization and its targeting to the lipid rafts in the 
plasma membrane during virus assembly (Zhou et al., 
1994; Resh, 2004; Wright et al., 2009). Nef on the 
other hand comprises many virulence factors to modify 
the cellular environment of infected cells to facilitate 
viral replication and evade detection by cells of the 
immune system (Collins et al., 1998). It has been 
reported that NMT1 myristoylates Gag in vivo and 
inhibiting NMT1 negatively affects HIV production 
(Takamune et al., 2008). 
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